BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12019846)

  • 1. Low-dose gadobenate dimeglumine-enhanced MRI in the detection and characterization of focal liver lesions.
    Kirchin MA; Spinazzi A
    Acad Radiol; 2002 May; 9 Suppl 1():S121-6. PubMed ID: 12019846
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions.
    Fu GL; Du Y; Zee CS; Yang HF; Li Y; Duan RG; Zeng NL; Xiao DM
    J Comput Assist Tomogr; 2012; 36(1):14-9. PubMed ID: 22261765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
    Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
    AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma.
    Pradella S; Lucarini S; Colagrande S
    AJR Am J Roentgenol; 2012 Nov; 199(5):W662. PubMed ID: 23096214
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
    Pirovano G; Vanzulli A; Marti-Bonmati L; Grazioli L; Manfredi R; Greco A; Holzknecht N; Daldrup-Link HE; Rummeny E; Hamm B; Arneson V; Imperatori L; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
    Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
    AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration.
    Morana G; Grazioli L; Kirchin MA; Bondioni MP; Faccioli N; Guarise A; Schneider G
    Invest Radiol; 2011 Apr; 46(4):225-39. PubMed ID: 21102346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MultiHance in the dynamic phase of contrast enhancement: a pictorial assessment.
    Grazioli L; Kirchin M; Pirovano G; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S61-4. PubMed ID: 10608399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
    Kim YK; Kwak HS; Han YM; Kim CS
    J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
    Schneider G; Maas R; Schultze Kool L; Rummeny E; Gehl HB; Lodemann KP; Kirchin MA
    Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast.
    Hylton NM
    AJR Am J Roentgenol; 2003 Sep; 181(3):677-8. PubMed ID: 12933458
    [No Abstract]   [Full Text] [Related]  

  • 15. MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine.
    Brismar TB; Kartalis N; Kylander C; Albiin N
    Eur Radiol; 2012 Mar; 22(3):633-41. PubMed ID: 21953376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI.
    Khouri Chalouhi K; Papini GDE; Bandirali M; Sconfienza LM; Di Leo G; Sardanelli F
    Eur J Radiol; 2014 Jul; 83(7):1245-1249. PubMed ID: 24816087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of hepatocellular carcinoma with dynamic MR imaging during intraarterial infusion of gadopentetate dimeglumine.
    Fujita T; Ito K; Choji T; Honjo K; Matsumoto T; Arita T; Nakanishi T
    AJR Am J Roentgenol; 1994 Oct; 163(4):865-6. PubMed ID: 8092025
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter testing of gadobenate dimeglumine in magnetic resonance imaging of focal liver disease.
    Spinazzi A; Pirovano G; Ratcliffe G; Pezzoli C; Rosati G
    Acad Radiol; 1996 Aug; 3 Suppl 2():S415-6. PubMed ID: 8796618
    [No Abstract]   [Full Text] [Related]  

  • 19. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage.
    Colosimo C; Ruscalleda J; Korves M; La Ferla R; Wool C; Pianezzola P; Kirchin MA
    Invest Radiol; 2001 Feb; 36(2):72-81. PubMed ID: 11224754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.